Fiche publication
Date publication
octobre 2014
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUILLAULT Gérard
Tous les auteurs :
Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Sirvent N, Yakouben K, Schmitt C, Gandemer V, Reguerre Y, Couillault G, Mechinaud F, Cayuela JM
Lien Pubmed
Résumé
Studies in adults have shown that an early molecular response to imatinib predicts clinical outcome in chronic myeloid leukemia (CML). We investigated the impact of the BCR-ABL1 transcript level measured 3 months after starting imatinib in a cohort of 40 children with CML. Children with a BCR-ABL1/ABL ratio higher than 10% at 3 months after the start of imatinib had a larger spleen size and a higher white blood cell count compared with those with BCR-ABL1/ABL ≤10%. Children with BCR-ABL1/ABL ≤10% 3 months after starting imatinib had higher rates of complete cytogenetic response and major molecular response at 12 months compared with those with BCR-ABL1/ABL >10%. With a median follow-up of 71 months (range, 22-96 months), BCR-ABL1/ABL ≤10% correlated with better progression-free survival. Thus, early molecular response at 3 months predicts outcome in children treated with imatinib for CML. This trial was registered at www.clinicaltrials.gov as #NCT00845221.
Mots clés
Adolescent, Benzamides, therapeutic use, Child, Child, Preschool, Cytogenetic Analysis, Disease-Free Survival, France, Fusion Proteins, bcr-abl, genetics, Humans, Imatinib Mesylate, Infant, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Piperazines, therapeutic use, Pyrimidines, therapeutic use
Référence
Blood. 2014 10 9;124(15):2408-10
